The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed? image

The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed?

May 22, 2024
01:00PM - 02:00PM EDT
Online Event
Overview

Maintenance therapy remains standard for most myeloma patients in today's treatment landscape. How has that changed throughout myeloma treatment history and what could the future of maintenance therapy look like? We look forward to hearing Dr. Sam Rubinstein's thoughts on the subject.

Agenda
1:00 PM
Introductions
Marisol Garcia

Marisol introduces the agenda of the event and featured speaker Dr. Sam Rubinstein.

1:05 PM
Presentation
Dr. Samuel Rubinstein

Dr. Sam Rubinstein shares his thoughts on maintenance therapy.

 

1:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Marisol Garcia

Marisol Garcia

Marisol es la manager de operaciones de eventos en la fundación de HealthTree. En conjunto con los Managers de educación trabajan para traer reuniones de diferentes temas de interés para los pacientes. Estudió ingeniería industrial y aprovecha sus conocimientos para hacer lo que le apasiona, coordinar eventos mientras enseña y ayuda a pacientes y sus familias. Su misión es hacer llegar nuestro programa a más gente, tanto en inglés como en español.
Healthtree contact Dr. Samuel Rubinstein

Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.